Figures & data
Figure 1. Clinical scores of the 20 patients who opted for ACS treatment after their earlier placebo treatment did not differ significantly from the clinical scores of patients who decided not to participate. Bars represent mean ± 95% CI. [Auth
Figure 2. Response shift measurement using the “then-test”. When measured at the end of the treatment (“3”), patients may rate their initial performance differently (“2”) from how they actually perceived it at the start of the treatment (“1”).
Figure 3. Clinical scores before and 3 and 12 months after placebo and ACS treatment (n = 20). A. VAS for pain. B. KSCRS. C. KOOS overall score. D. WOMAC. Patients reported improvement for all scores during placebo treatment, with short-term follow-up (3 months) and extended follow-up (12 months). For ACS treatment, significant short-term improvement is only reported for VAS (pain) after 3 months of treatment. The KSCRS (B) was the only score that showed improvement after the combination of placebo and ACS treatment. Bars represent mean ± 95% CI.
